Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | MC5R | P33032 | 1/20 | 0.36 |
| ▸ | MC3R | P41968 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12465971 | 1.00 | YTHDC1 (0.42) | YTHDC1SLC6A2SLC6A4KMT2AMEN1 | |
| SCHEMBL27938356 | 1.00 | YTHDC1 (0.42) | YTHDC1SLC6A2SLC6A4KMT2AMEN1 | |
| SCHEMBL1192262 | 0.81 | SLC18A3 (0.44) | YTHDC1SLC6A2SLC6A4KMT2AMEN1 | |
| SCHEMBL1192148 | 0.81 | SLC18A3 (0.44) | YTHDC1SLC6A2SLC6A4KMT2AMEN1 | |
| SCHEMBL12468294 | 0.81 | SLC18A3 (0.44) | YTHDC1SLC6A2SLC6A4KMT2AMEN1 | |
| SCHEMBL12466177 | 0.81 | SLC18A3 (0.44) | YTHDC1SLC6A2SLC6A4KMT2AMEN1 | |
| SCHEMBL23583787 | 0.80 | YTHDC1 (0.46) | YTHDC1SLC6A2SLC6A4KMT2AMEN1 | |
| SCHEMBL27987897 | 0.80 | YTHDC1 (0.46) | YTHDC1SLC6A2SLC6A4KMT2AMEN1 | |
| SCHEMBL14795012 | 0.80 | YTHDC1 (0.46) | YTHDC1SLC6A2SLC6A4KMT2AMEN1 | |
| SCHEMBL3376962 | 0.77 | YTHDC1 (0.58) | YTHDC1SLC6A2SLC6A4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459535-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2015-03-25 | — | — | EP | disclosed |
| US-20140288076-A1 | HETEROARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2014-09-25 | — | — | US | disclosed |
| US-8778951-B2 | Heteroaryl compounds and their uses | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20130303507-A1 | SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-11-14 | — | — | US | disclosed |
| US-20130172354-A1 | HETEROARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172354-A1 | HETEROARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | YTHDC1 4199/4885SLC6A2 3437/4885SLC6A4 3612/4885 |
| US-20140288076-A1 | HETEROARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | YTHDC1 4199/4885SLC6A2 3437/4885SLC6A4 3612/4885 |
| US-20130303507-A1 | SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | YTHDC1 4459/4885SLC6A2 4440/4885SLC6A4 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.